{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-035521","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2025-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.464745+00:00","generated_at":"2026-05-16T18:51:26.113778+00:00","sec_items":["9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tivic Health secures BARDA Techwatch meeting for Entolimod ARS program","bullets":["Meeting with BARDA's Radiological and Nuclear Medical Countermeasures Program staff to discuss Entolimod for acute radiation syndrome.","Tivic will present clinical data, manufacturing readiness, and BLA preparations; meeting may lead to funding or purchasing.","Entolimod has FDA Fast Track and Orphan Drug designations for ARS.","CEO states this supports strategy for government partnership or acquisition pathway."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-035521","json":"https://secwatch.observer/filing/0001437749-25-035521.json","markdown":"https://secwatch.observer/filing/0001437749-25-035521.md","text":"https://secwatch.observer/filing/0001437749-25-035521.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000143774925035521/0001437749-25-035521-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000143774925035521/tivc20251117_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:51:26.113778+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}